Document is current
Any future updates will be listed below
-
Authors
Ozawa, Yuichi https://orcid.org/0000-0003-3798-3488
Koh, Yasuhiro
Shibaki, Ryota
Harutani, Yuhei
Akamatsu, Hiroaki
Hayata, Atsushi
Sugimoto, Takeya
Kitamura, Yuka
Fukuoka, Junya
Nakanishi, Masanori
Yamamoto, Nobuyuki
-
Funding
Funding for this research was provided by:
JSPS KAKENHI (JP21K07247)
- License Information
-
More Information
Article History
Received: 6 May 2024
Accepted: 9 October 2024
First Online: 2 November 2024
Declarations
:
: Yuichi Ozawa received honoraria from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Merck Sharp & Dohme K.K., and Ono Pharmaceutical Co., Ltd. Yasuhiro Koh received grants from Chugai Pharmaceutical Co., and honoraria from Chugai Pharmaceutical Co. Hiroaki Akamatsu received honoraria from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Merck Sharp & Dohme K.K., and Ono Pharmaceutical Co., Ltd., Yuka Kitamura have stock of N Lab Co., Ltd., Junya Fukuoka have stock of N Lab Co., Ltd., PathPresenter, and Pathology Institute, Nobuyuki Yamamoto received grants from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Merck Sharp & Dohme K.K., Bristol-Myers Squibb Japan, and Ono Pharmaceutical Co., Ltd., and honoraria from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Merck Sharp & Dohme K.K., and Ono Pharmaceutical Co., Ltd., and consulting fees from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Merck Sharp & Dohme K.K., and Ono Pharmaceutical Co., Ltd.
: This study was approved by the institutional review board of Wakayama Medical University (#2654).
: Given the retrospective nature of the study, consent was not obtained; instead, an opt-out approach was utilized.
: Not applicable.
